Ares Financial Consulting’s Revolution Medicines RVMD Stock Holding History

Ares Financial Consulting’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.37K	Buy	+34	New	+$4.97K	﹤0.01%	659

Other funds holding RVMD

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ares Financial Consulting's RVMD Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Revolution Medicines (RVMD) in Q2 2026: 34 shares worth $6.37K. The stake represents ﹤0.01% of the portfolio and ranks #659 among its holdings.

264 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Ares Financial Consulting held 34 shares of Revolution Medicines worth $6.37K as of Q2 2026.
Revolution Medicines was a new Ares Financial Consulting position in Q2 2026.
Revolution Medicines made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #659 holding.
264 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.